To control and beyond: moving towards eliminating the global tuberculosis threat

被引:50
作者
Brewer, TF
Heymann, SJ
机构
[1] Brigham & Womens Hosp, Boston, MA 02115 USA
[2] Harvard Univ, Sch Med, Boston, MA USA
[3] Harvard Univ, Sch Publ Hlth, Dept Soc Human Dev & Hlth, Boston, MA 02115 USA
关键词
D O I
10.1136/jech.2003.008664
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
For 10 years the World Health Organisation has had a single answer to the deadly threat of tuberculosis (TB) provide treatment to smear positive patients and watch them take it. In contrast with confident statements about how global TB would be brought under control when directly observed therapy, short course (DOTS) was introduced, TB continues to rise worldwide. The introduction of selected multiple drug resistant TB treatment programmes, "DOTS-Plus'', although important, also focuses on therapy for active TB. HIV endemic countries in particular have experienced tremendous increases in TB despite having DOTS programmes. A critical review of recent epidemiological data and computer models shows that the present international strategy of concentrating on providing treatment for smear positive TB, DOTS and DOTS-Plus, is likely to have only a modest impact on population based TB control. Effective global TB control will require strategies that go beyond relying on treatment of people with active disease.
引用
收藏
页码:822 / 825
页数:4
相关论文
共 44 条
[1]   Management of an outbreak of tuberculosis in a small community [J].
Allos, BM ;
Gensheimer, KF ;
Bloch, AB ;
Parrotte, D ;
Horan, JM ;
Lewis, V ;
Schaffner, W .
ANNALS OF INTERNAL MEDICINE, 1996, 125 (02) :114-117
[2]   Transmission of Mycobacterium tuberculosis from patients smear-negative for acid-fast bacilli [J].
Behr, MA ;
Warren, SA ;
Salamon, H ;
Hopewell, PC ;
de Leon, AP ;
Daley, CL ;
Small, PM .
LANCET, 1999, 353 (9151) :444-449
[3]   Molecular and geographic patterns of tuberculosis transmission after 15 years of directly observed therapy [J].
Bishai, WR ;
Graham, NMH ;
Harrington, S ;
Pope, DS ;
Hooper, N ;
Astemborski, J ;
Sheely, L ;
Vlahov, D ;
Glass, GE ;
Chaisson, RE .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (19) :1679-1684
[4]  
BLANC L, 2001, WHOCDSTB200111
[5]  
Bleed D, 2000, Curr Opin Pulm Med, V6, P174, DOI 10.1097/00063198-200005000-00002
[6]   Evaluation of tuberculosis control policies using computer simulation [J].
Brewer, TF ;
Heymann, SJ ;
Colditz, GA ;
Wilson, ME ;
Auerbach, K ;
Kane, D ;
Fineberg, HV .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 276 (23) :1898-1903
[7]  
Brudney K, 1991, Semin Respir Infect, V6, P261
[8]   Tuberculosis in sub-Saharan Africa: A regional assessment of the impact of the human immunodeficiency virus and National Tuberculosis Control Program quality [J].
Cantwell, MF ;
Binkin, NJ .
TUBERCLE AND LUNG DISEASE, 1996, 77 (03) :220-225
[9]  
Churchyard CJ, 1999, INT J TUBERC LUNG D, V3, P791
[10]   A 62-DOSE, 6-MONTH THERAPY FOR PULMONARY AND EXTRAPULMONARY TUBERCULOSIS - A TWICE-WEEKLY, DIRECTLY OBSERVED, AND COST-EFFECTIVE REGIMEN [J].
COHN, DL ;
CATLIN, BJ ;
PETERSON, KL ;
JUDSON, FN ;
SBARBARO, JA .
ANNALS OF INTERNAL MEDICINE, 1990, 112 (06) :407-415